Table 2.
Control |
Intervention |
|||
---|---|---|---|---|
Category | Baseline, N (%) | End of trial, N (%) | Baseline, N (%) | End of trial, N (%) |
Children | ||||
<65 (µg/day) (EAR) | 5 (3.62) | 1 (0.74) | 1 (0.71) | 6 (4.32) |
65–300 (µg/day) | 123 (89.13) | 114 (84.44) | 128 (90.78) | 119 (85.61) |
>300 (µg/day) (UL) | 10 (7.25) | 20 (14.81) | 12 (8.51) | 14 (10.07) |
Adults | ||||
<85 (µg/day) (EAR) | 3 (1.09) | 4 (1.53) | 2 (0.72) | 7 (2.58) |
85–600 (µg/day) | 260 (94.55) | 243 (93.10) | 263 (94.95) | 243 (89.67) |
>600 (µg/day) (UL) | 12 (4.36) | 14 (5.36) | 12 (4.33) | 21 (7.75) |
EAR, estimated average requirement; UL, tolerable upper limit.